10:59 AM EDT, 07/09/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) will likely focus on its updated 2025 guidance and the impact of tariffs during its Q2 earnings call next week, BofA Securities said in a note Wednesday.

Ahead of the release of the company's quarterly results on July 16, the firm said the company's guidance will likely take into account its sales outlook and improved foreign exchange, while its estimated tariff impact "is subject to significant uncertainty as policy remains in fluid."

The company is also expected to discuss the impact of ustekinumab biosimilars on Stelara, pipeline catalysts especially icotrokinra, launch progress for various brands, and MedTech challenges, according to the note.

BofA said it believes Johnson & Johnson ( JNJ ) shares are "fairly valued" because of the company's "about-average" long-term earnings per share growth.

BofA maintained the stock's neutral rating and $161 price objective.

Price: 155.49, Change: -0.30, Percent Change: -0.19